Incannex Healthcare (IXHL) to Announce Quarterly Earnings on Monday

Incannex Healthcare (NASDAQ:IXHL) is expected to post its Q4 2026 results before the market opens on Monday, September 7th. Analysts expect Incannex Healthcare to announce earnings of ($0.1350) per share and revenue of $0.20 million for the quarter. Individuals may review the information on the company’s upcoming Q4 2026 earning results page for the latest details on the call scheduled for Wednesday, September 30, 2026 at 9:30 AM ET.

Incannex Healthcare Trading Down 0.3%

NASDAQ IXHL opened at $3.24 on Friday. Incannex Healthcare has a 1-year low of $2.49 and a 1-year high of $20.31. The firm’s fifty day simple moving average is $3.33 and its 200-day simple moving average is $3.75. The company has a market capitalization of $38.77 million, a PE ratio of -2.09 and a beta of 6.97.

Hedge Funds Weigh In On Incannex Healthcare

Hedge funds have recently bought and sold shares of the business. LPL Financial LLC raised its holdings in Incannex Healthcare by 639.1% during the fourth quarter. LPL Financial LLC now owns 335,373 shares of the company’s stock valued at $120,000 after buying an additional 290,000 shares in the last quarter. Virtu Financial LLC boosted its stake in shares of Incannex Healthcare by 87.3% during the 4th quarter. Virtu Financial LLC now owns 753,675 shares of the company’s stock worth $270,000 after acquiring an additional 351,232 shares in the last quarter. Arete Wealth Advisors LLC boosted its stake in shares of Incannex Healthcare by 88.7% during the 4th quarter. Arete Wealth Advisors LLC now owns 2,223,450 shares of the company’s stock worth $796,000 after acquiring an additional 1,044,862 shares in the last quarter. Finally, Jane Street Group LLC increased its holdings in shares of Incannex Healthcare by 547.4% during the 4th quarter. Jane Street Group LLC now owns 1,491,835 shares of the company’s stock valued at $534,000 after acquiring an additional 1,261,385 shares during the last quarter. 0.43% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

IXHL has been the topic of a number of recent research reports. Alliance Global Partners assumed coverage on Incannex Healthcare in a research note on Monday, June 8th. They issued a “buy” rating and a $18.00 target price on the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Incannex Healthcare in a research note on Friday, July 17th. Finally, Wall Street Zen raised Incannex Healthcare from a “sell” rating to a “hold” rating in a research note on Saturday, May 23rd. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Incannex Healthcare has a consensus rating of “Hold” and an average price target of $18.00.

Incannex Healthcare Company Profile

Incannex Healthcare Ltd is a clinical-stage biopharmaceutical company focused on developing novel therapies that combine cannabinoid and psychedelic compounds. Headquartered in Melbourne, Australia, with research operations in the United States, the company seeks to leverage the therapeutic potential of its proprietary formulations to address a range of medical conditions. Incannex is publicly traded on the NASDAQ under the ticker IXHL and maintains a presence in both Australia and North America.

The company’s research and development pipeline includes multiple product candidates in various stages of clinical evaluation.